CN103467369B - The preparation method of nimodipine impurity I - Google Patents
The preparation method of nimodipine impurity I Download PDFInfo
- Publication number
- CN103467369B CN103467369B CN201310464944.XA CN201310464944A CN103467369B CN 103467369 B CN103467369 B CN 103467369B CN 201310464944 A CN201310464944 A CN 201310464944A CN 103467369 B CN103467369 B CN 103467369B
- Authority
- CN
- China
- Prior art keywords
- nimodipine
- impurity
- preparation
- add
- back flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a kind of preparation method of nimodipine impurity I, belong to pharmaceutical technology sectors.Preparation method of the present invention, adopts nimodipine dehydrogenation oxidation method, comprises the following steps: be dissolved in by nimodipine in solvent, add oxygenant, back flow reaction, add activated carbon decolorizing, steams and desolventizes, obtain yellow oil nimodipine impurity I after suction filtration; Highly purified nimodipine impurity I is prepared by chemical synthesis process, pharmacology and the toxicological study of impurity I can be further used for, to nimodipine product impurity side effect research sampling support, simultaneously can as nimodipine related substance HPLC analysis impurity working standard.
Description
Technical field
The present invention relates to the preparation method of nimodipine impurity I.
Background technology
Nimodipine (Nimodipine), has another name called that sharp class enlightening is flat, nimodipine, chemistry sec.-propyl-2-methoxyethyl-1 by name, 4-dihydro-2,6-dimethyl-4(3-nitrophenyl)-3,5-pyridine dicarboxylates, it is s-generation Isosorbide-5-Nitrae-dihydropyridine calcium channel antagonist.For selectively acting is in cerebrovascular Ca2+ overloading vasodilator, can effectively control intracellular calcium content.Be mainly used in the functional disorders of brain that apoplexy migraine, cerebral vasospasm, vascular dementia, sudden deafness, multiple ischemic cerebrovascular disease, dysmnesia disease and a variety of causes cause clinically.
Nimodipine impurity I (European Pharmacopoeia is defined as impurity A) its structural formula of Chinese Pharmacopoeia 2010 editions definition is:
Chemistry 2,6-dimethyl-4-(3-nitrophenyl by name)-3,5-dinicotinic acid-2-methoxyimino acetic acid isopropyl esters, there is liver renal toxicity, Chinese Pharmacopoeia 2010 editions and European Pharmacopoeia 7.0 editions control overflow≤0.1% to this impurity.
The synthetic method of existing bibliographical information impurity I is: get nimodipine raw material anhydrous alcohol solution, removes solvent under reduced pressure, column chromatography for separation under ultraviolet after long-time irradiation, and it is impurity I that collection component obtains red oil, productive rate 54%.But we are through test conditions duplicate acknowledgment, the reaction of this ultraviolet degradation is carried out very slow, and irradiate 1 time-of-week, TLC analysing impurity I only transforms about 10%, cannot prepare pure impurity I.Therefore, ultraviolet degradation method speed of response is slow, and low conversion rate, is not suitable for the preparation of impurity I standard substance.
Summary of the invention
The object of this invention is to provide a kind of high purity of nimodipine impurity I, high conversion, fast preparation method.
The preparation method of nimodipine impurity I of the present invention, adopt nimodipine dehydrogenation oxidation method, step comprises: be dissolved in solvent by nimodipine raw material, add oxygenant, back flow reaction, add activated carbon decolorizing, steam after suction filtration and desolventize, obtain yellow oil nimodipine impurity I.
Described solvent is the one in benzene, toluene, hexanaphthene or isobutyl acetate, preferred toluene;
Described nimodipine and the weight ratio of solvent are 1: 10 ~ 20;
Described back flow reaction temperature is 60 ~ 130 DEG C, preferably 105 ~ 110 DEG C; Reflux time is 1 ~ 6 hour, preferably 2 ~ 3 hours;
Described oxygenant is the one in Manganse Dioxide, nitric acid or hydrogen peroxide, preferred Manganse Dioxide; The mol ratio of nimodipine and oxygenant is 1: 2 ~ 6, preferably 1: 4;
The weight ratio of nimodipine and gac is 1: 0.2 ~ 0.7, preferably 1: 0.5.
Compared with prior art, the present invention has following beneficial effect:
By selecting suitable dehydrogenation oxidation agent, make the unsaturated fused heterocycle dehydroaromatizationof of nimodipine generate fused heterocycle aromatic hydrocarbons, and can not affect other oxidizable group, for preparing, impurity I is more satisfactory;
This method yield can reach more than 95%, HPLC content can reach more than 98%;
Highly purified nimodipine impurity I is prepared by chemical synthesis process, pharmacology and the toxicological study of impurity I can be further used for, to nimodipine product impurity side effect research sampling support, simultaneously can as nimodipine related substance HPLC analysis impurity working standard.
Embodiment
Below in conjunction with embodiment, the present invention is described further.
Embodiment 1
Add nimodipine (20.9g being equipped with in thermometer, reflux condensing tube and churned mechanically reaction flask, 0.05mol), Manganse Dioxide (17.4g, 0.2mol) and 300ml benzene, be warming up to backflow under stirring, 78 ~ 81 DEG C of back flow reaction 2h, add gac 10g again, insulation backflow 30min, suction filtration obtains light yellow filtered liquid, underpressure distillation steams benzene, obtain pale yellow oil 19.2g, yield 92%, content 98.2%.
Embodiment 2
Add nimodipine (20.9g being equipped with in thermometer, reflux condensing tube and churned mechanically reaction flask, 0.05mol), Manganse Dioxide (17.4g, 0.2mol) and 300ml toluene, be warming up to backflow under stirring, 105 ~ 110 DEG C of back flow reaction 2h, add gac 10g again, insulation backflow 30min, suction filtration obtains light yellow filtered liquid, underpressure distillation steams toluene, obtain pale yellow oil 20.2g, yield 97%, content 98.9%.
Embodiment 3
Add nimodipine (20.9g being equipped with in thermometer, reflux condensing tube and churned mechanically reaction flask, 0.05mol), nitric acid (12.6g, 0.2mol) and 350ml hexanaphthene, be warming up to backflow under stirring, 78 ~ 81 DEG C of back flow reaction 2h, add gac 10g again, insulation backflow 30min, suction filtration obtains light yellow filtered liquid, underpressure distillation steams hexanaphthene, obtain pale yellow oil 17.7g, yield 85%, content 90.5%.
Embodiment 4
Add nimodipine (20.9g being equipped with in thermometer, reflux condensing tube and churned mechanically reaction flask, 0.05mol), hydrogen peroxide (scale 6.8g, 0.2mol) and 350ml isobutyl acetate, be warming up to backflow under stirring, 115 ~ 118 DEG C of back flow reaction 3h, add gac 10g again, insulation backflow 30min, suction filtration obtains light yellow filtered liquid, underpressure distillation steams isobutyl acetate, obtain pale yellow oil 18.9g, yield 91%, content 89.2%.
Claims (1)
1. the preparation method of a nimodipine impurity I, it is characterized in that: add nimodipine 20.9g, hydrogen peroxide 6.8g being equipped with in thermometer, reflux condensing tube and churned mechanically reaction flask, and 350ml isobutyl acetate, be warming up to backflow under stirring, 115 ~ 118 DEG C of back flow reaction 3h, add gac 10g again, insulation backflow 30min, suction filtration obtains light yellow filtered liquid, underpressure distillation steams isobutyl acetate, obtain pale yellow oil 18.9g, yield 91%, content 89.2%;
The structural formula of described nimodipine impurity I is as follows:
。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310464944.XA CN103467369B (en) | 2013-09-30 | 2013-09-30 | The preparation method of nimodipine impurity I |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310464944.XA CN103467369B (en) | 2013-09-30 | 2013-09-30 | The preparation method of nimodipine impurity I |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103467369A CN103467369A (en) | 2013-12-25 |
| CN103467369B true CN103467369B (en) | 2015-11-04 |
Family
ID=49792450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310464944.XA Active CN103467369B (en) | 2013-09-30 | 2013-09-30 | The preparation method of nimodipine impurity I |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103467369B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110511180A (en) * | 2019-06-12 | 2019-11-29 | 北京鑫开元医药科技有限公司 | A kind of Preparation method and use of pyridine derivate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998007698A1 (en) * | 1996-08-23 | 1998-02-26 | Lusochimica S.P.A. | A process for the preparation of dihydropyridines |
| US20080125595A1 (en) * | 2006-11-28 | 2008-05-29 | Navinta Llc. | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions |
| CN102174012A (en) * | 2011-03-11 | 2011-09-07 | 山东新华制药股份有限公司 | Preparation method of nimodipine |
-
2013
- 2013-09-30 CN CN201310464944.XA patent/CN103467369B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998007698A1 (en) * | 1996-08-23 | 1998-02-26 | Lusochimica S.P.A. | A process for the preparation of dihydropyridines |
| US20080125595A1 (en) * | 2006-11-28 | 2008-05-29 | Navinta Llc. | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions |
| CN102174012A (en) * | 2011-03-11 | 2011-09-07 | 山东新华制药股份有限公司 | Preparation method of nimodipine |
Non-Patent Citations (2)
| Title |
|---|
| Oxidation of 4-Aryl- and 4-Alkyl-Substituted 2,6-Dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihidropyridines by Human Liver Microsomes and Immunochemical Evidence for the Involvement of a Form of Cytochrome P-450;Ronald H. Bocker，等;《Journal of Medicinal Chemistry》;19861231;第29卷(第9期);第1596-1603页 * |
| 尼莫地平欧洲药典杂质合成与生产过程杂质控制;张博;《山东大学硕士学位论文》;20130515;第23-24页第3.1.3.1节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103467369A (en) | 2013-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103087048B (en) | Method for purifying esomeprazole sodium | |
| CN100534982C (en) | Processes for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine and hydrochloride thereof | |
| CN103467369B (en) | The preparation method of nimodipine impurity I | |
| CN1253426C (en) | Process for extracting, preparing and purifying gamma methyllinolenate from algae | |
| CN105949184B (en) | Refining method of arotinolol hydrochloride | |
| CN107033114B (en) | Method for separating and purifying dihydromyricetin | |
| KR101001646B1 (en) | Method of preparing r-+-lansoprazole and intermediate used therein | |
| CN104710373A (en) | Preparation method for high-purity cyproconazole isomer | |
| CN113980012A (en) | Purification method of emtricitabine | |
| CN101550077A (en) | Manufacturing method of bicyclohexyl derivative | |
| CN104844681A (en) | L-crystal form eplerenone refining method | |
| CN106146403A (en) | A kind of purification process of grace miscellaneous Shandong amine | |
| RU2005118102A (en) | PHARMACOLOGICALLY ACTIVE COMPOUND OF THE NEW SLEEPING STATE DOWER-PHERON FOR MONITORING STRESSES AND AGING PROCESSES, METHOD FOR ITS ISOLATION AND DETERMINATION (CHARACTERIZATION) | |
| WO2010126138A1 (en) | Novel crystal forms of tricyclic benzopyran compound and processes for producing same | |
| CN109761885A (en) | A kind of method for splitting of argatroban isomer impurities | |
| CN102260208A (en) | New preparation process of 4-pyridine butanol | |
| JP6287290B2 (en) | Method for producing trans-1,2-diaminocyclohexane | |
| CN103408439A (en) | Chemical synthetic method of norbelladine | |
| JP2018016569A (en) | Production method of (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile oxalate | |
| WO2017093192A1 (en) | Crystallization of 25-hydroxy-7-dehydrocholsterol | |
| CN103058850B (en) | A kind of method preparing A Li vitamin A acid | |
| CN104098510B (en) | Method for extracting lappaconitine from aconitum sinomontanum plant roots | |
| CN100534989C (en) | Resolving process of (RS)-benzdioxan-2-formic acid | |
| CN111909081B (en) | Method for purifying pyriproxyfen technical, product obtained by method and application of pyriproxyfen technical | |
| Gu et al. | A new method of extraction and purification of solanesol from tobacco extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |